PancreaSure for Early Detection of Pancreatic Cancer in Increased-Risk Patients
Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer and one of the leading causes of cancer-related mortality worldwide, largely due to late-stage diagnosis. Early-stage disease is frequently asymptomatic, and currently available diagnostic approaches lack sufficient sensitivity for population-based or high-risk screening. As a result, most patients are diagnosed at advanced stages, when curative treatment options are limited and survival outcomes are poor.
PancreaSure is a blood-based multiplex immunoassay designed to aid in the early detection of PDAC in individuals at increased risk due to familial or hereditary factors. The assay measures five circulating biomarkers associated with pancreatic cancer biology: intercellular adhesion molecule 1 (ICAM1), tissue inhibitor of metalloproteinases 1 (TIMP1), cathepsin D (CTSD), thrombospondin 1 (THBS1), and carbohydrate antigen 19-9 (CA 19-9). Results are integrated through a validated diagnostic algorithm to provide a qualitative classification of positive or negative.
PancreaSure is optimized to detect pancreatic cancer at early stages, including stage I and II disease, when surgical intervention and other therapies are more likely to be effective. The test is offered as a laboratory-developed test through Immunovia’s CAP- and CLIA-certified laboratory. Clinical validation was performed in the CLARITI study, which included high-risk individuals with familial or hereditary risk for PDAC. In this study of 1,066 blood samples, PancreaSure demonstrated a sensitivity of 78% for early-stage pancreatic cancer and a specificity of 94% in individuals without cancer, supporting its clinical utility as an adjunctive screening and diagnostic aid in appropriate high-risk populations.
A positive result indicates that the biomarker profile is consistent with an increased likelihood of pancreatic cancer. This finding does not establish a definitive diagnosis but warrants prompt clinical evaluation, including appropriate imaging and/or tissue biopsy, to confirm or exclude malignancy.
A negative result indicates that the biomarker profile is not consistent with pancreatic cancer at the time of testing. A negative result does not exclude the presence of pancreatic cancer, particularly in very early disease or in cases where biomarker levels are below the assay’s detection threshold. Ongoing surveillance may be appropriate in high-risk individuals.
Negative
Plasma (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- Gastroenterology. 2025 Oct 27:S0016-5085(25)05976-1 [PMID: 41143761]
- Clin Transl Gastroenterol. 2022 Feb 14;13(3). [PMID: 35166713]
- Curr Oncol. 2025 Nov 13;32(11):638. [PMID: 41294700]
- J Natl Cancer Inst. 2017 Apr 1;109(4):djw266. [PMID: 28376157]
- Immunovia AB. PancreaSure Test Information and Clinical Validation Data.